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AbstrAct
Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein, which controls 
several physiological and pathological events. FSTL1 expression is deregulated in 
many tumors, but its contribution to colon carcinogenesis is not fully understood. 
Here, we investigated the expression and functional role of FSTL1 in colorectal 
cancer (CRC). A significant increase of FSTL1 was seen in human CRC as compared 
to the surrounding non-tumor tissues and this occurred at both RNA and protein 
level. Knockdown of FSTL1 in CRC cells with a specific antisense oligonucleotide 
(AS) reduced expression of regulators of the late G1 phase, such as phosphorylated 
retinoblastoma protein, E2F-1, cyclin E and phospho-cyclin-dependent kinase-2, and 
promoted accumulation of cells in the G1 phase of the cell cycle thus resulting in 
diminished cell proliferation. Consistently, recombinant FSTL1 induced proliferation of 
normal intestinal epithelial cells through an ERK1/2-dependent mechanism. Cell cycle 
arrest driven by FSTL1 AS in CRC cells was accompanied by activation of caspases 
and subsequent induction of apoptosis. Moreover, FSTL1 knockdown made CRC cells 
more susceptible to oxaliplatin and irinotecan-induced death. Data indicate that FSTL1 
is over-expressed in human CRC and suggest a role for this protein in favouring 
intestinal tumorigenesis.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 58), pp: 31278-31290
IntroductIon
Colorectal cancer (CRC), one of the most common 
cancers in both men and women, is the fourth leading 
cause of cancer-related mortality worldwide, mainly due 
to the lack of effective treatment of advanced disease 
[1]. Sporadic disease, in which there is no family history, 
accounts for approximately 70 percent of all CRCs. The 
pathogenesis of CRC is not fully understood but a large 
body of evidence suggests that CRC results from the 
accumulation of genetic and epigenetic modifications, 
which alter pathways regulating proliferation, apoptosis, 
and angiogenesis, and CRC cell growth and survival are 
favored by many molecules produced within the tumor 
microenvironment [2, 3].
Follistatin-like protein 1 (FSTL1), also named 
transforming growth factor (TGF)β1- stimulated 
clone 36 (TSC-36) or follistatin-related protein, is an 
extracellular secreted glycoprotein, which belongs to 
the BM-40/SPARC/osteonectin family. FSTL1 is widely 
expressed in human tissues and plays key functions in the 
regulation of cell survival, proliferation, differentiation 
and migration of many cell types [4]. FSTL1 is also a 
regulator of embryonic organogenesis [5] and exerts either 
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detrimental or protective effects depending on the context 
and experimental setting analyzed [6, 7]. Disconnected 
(disco)-interacting protein 2 homolog A (DIP2A) is a 
member of the DIP2 protein family encoded by Dip2a 
gene, which mediates FSTL1 function and is expressed in 
neurons, mesenchymal, endothelial, smooth muscle cells 
and cardiomyocytes [8, 9]. Altered expression of FSTL1 
has been described in malignancies [10–14], even though 
its contribution to carcinogenesis remains controversial as 
FSTL1 can either positively or negatively regulate cancer 
cell growth and survival [10–14]. For instance, FSTL1 
overexpression has been associated with poor prognosis 
of glioblastoma [10], progression of prostate cancer [11] 
and bone metastasis [12]. Moreover, experimental studies 
have shown that FSTL1 inhibition promotes apoptotis 
of lung cancer cells [13]. In contrast, FSTL1 exerts 
tumor-suppressive actions in ovarian and endometrial 
carcinogenesis and its expression is down-regulated in 
metastatic clear-cell renal-cell carcinoma [14, 15]. Recent 
studies have also documented altered expression of FSTL1 
in human CRC, but divergent results have been provided 
regarding the cell sources of the cytokine and its role in 
the regulation of CRC cell behavior [16–18]. Therefore, 
we here investigated whether CRC cells produce FSTL1 
and assessed the contribution of FSTL1 in the growth and 
survival of CRC cells. 
results
Fstl1 is upregulated in human sporadic crc
FSTL1 RNA transcripts were significantly increased 
in CRC samples as compared to non-tumoral samples 
(Figure 1A). Western blotting of total proteins extracted 
from freshly obtained samples and densitometry analysis 
of blots confirmed up-regulation of FSTL1 in the tumoral 
samples (Figure 1B). Consistent with the above data, 
FSTL1 was expressed in the CRC cell lines DLD-1, HCT-
116 and HT-29 and to a lesser extent in HCEC-1CT, a 
normal epithelial colon cell line (Figure 1C). Moreover, 
immunostaining of normal and tumoral colonic sections 
showed a more pronounced expression of FSTL1 in 
adenoma and CRC cells as compared to normal colonic 
epithelial cells (Figure 1D). A diffuse and intense staining 
of FSTL1-positive cells was also seen in the lamina 
propria compartment of adenoma and CRC sections 
(Figure 1D). 
Fstl1 positively controls crc cell growth
To determine whether FSTL1 regulates CRC cell 
proliferation, FSTL1 was inhibited in DLD-1 and HCT-
116 cells with a specific antisense (AS) oligonucleotide 
(Figure 2A). Cells transfected with FSTL1 AS exhibited 
a significant reduction of 5-bromodeoxyuridine (BrdU) 
incorporation as compared to cells transfected with 
control oligonucleotide (Figure 2B). By flow-cytometry, 
we then showed that the percentage of proliferating 
cells was reduced by FSTL1 knockdown (Figure 2C). 
Analysis of cell cycle revealed that FSTL1 AS treatment 
significantly increased the number of cells in G1 phase 
and decreased the number of cells accumulated in S and 
G2 phases (Figure 2D and Supplementary Figure 1A), 
suggesting that DNA replication is inhibited following 
FSTL1 knockdown. In eukaryotic cells, the initiation of 
DNA replication and entry into mitosis are orchestrated by 
cyclin/cyclin-dependent kinase (CDK) complexes, which 
are formed at specific stages of the cell cycle [19]. Cdk4, 
Cdk6 and cyclin E-Cdk2 complexes, which sequentially 
phosphorylate the retinoblastoma protein (Rb), regulate 
transition from G1 phase to S phase [19]. Inhibition of 
FSTL1 resulted in a marked reduction of proteins involved 
in late G1 cell cycle phase, such as phosphorylated-Rb (p-
Rb), E2F-1, cyclin E and phospho-Cdk2 (p-Cdk2) (Figure 
2E, right panel and Supplementary Figure 1B, right panel), 
with no modification of early G1 phase proteins (i.e. 
cyclin D1, D2, D3, Cdk4, Cdk6) (Figure 2E, left panel 
and Supplementary Figure 1B, left panel).
Fstl1 stimulates epithelial cell proliferation via 
erK1/2-dependent pathway
In the subsequent studies, we dissected the basic 
mechanism by which FSTL1 positively regulates epithelial 
cell growth. By real-time PCR and Western blotting, we 
initially showed that DIP2A was expressed in normal and 
neoplastic colon cell lines (Figure 3A, left and right panel, 
respectively). Next, normal epithelial colon cells (i.e. 
HCEC-1CT) were stimulated with recombinant human 
FSTL1 protein for 24–72 hours and cell proliferation was 
evaluated as above. Treatment of cells with recombinant 
FSTL1 enhanced cell growth and this effect was evident at 
each time point (Figure 3B). To examine whether FSTL1 
activates signalling pathways that control neoplastic 
cell proliferation, HCEC-1CT cells were left either 
unstimulated or stimulated with recombinant FSTL1 for 
different time points, and activation of NF-kB/p65, AKT 
and ERK1/2 MAP kinases was evaluated by Western 
blotting, using antibodies that recognise the active forms 
of these proteins. FSTL1 enhanced phosphorylation of 
AKT and ERK1/2 without affecting phosphorylation of 
NF-kB/p65 (Figure 3C). In parallel experiments, cells 
were pre-treated with either wortmannin, an inhibitor of 
AKT, or PD98059, an inhibitor of ERK1/2, prior to being 
stimulated with recombinant FSTL1. For these studies, we 
selected concentrations of wortmannin and PD98059, which 
selectively inhibit AKT and ERK1/2, respectively (not 
shown). Treatment of HCEC-1CT cells with Wortmannin 
did not affect FSTL1-induced cell proliferation (Figure 3D), 
while PD98059 significantly reduced FSTL1-driven cell 
growth (Figure 3E). 
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Figure 1: Fslt1 is overexpressed in human sporadic crc and in crc cell lines. (A) FSTL1 RNA transcripts were evaluated 
in specimens taken from both tumoral (T) and non-tumoral (NT) areas of 12 patients with CRC by real-time PCR and levels were normalized 
to β-actin. Data are expressed as mean ± SEM of all samples. (b) Total proteins extracted from both tumoral (T) and non-tumoral (NT) 
areas of 12 patients with CRC were evaluated for FSTL1 expression by Western blotting. β-actin was used as loading control. The figure 
is representative of two separate experiments in which similar results were obtained. Right inset. Quantitative analysis of FSTL1/β-actin 
protein ratio in total extracts of T and NT tissues taken from 12 patients with CRC, as measured by densitometry scanning of Western 
blots. Values are expressed in arbitrary units (a.u.) and indicate the mean ± S.E.M. of all experiments. (c) Total proteins extracted from 
3 CRC cell lines (i.e. DLD-1, HCT-116 and HT-29) and from the human colonic epithelial cell line (HCEC-1CT) were evaluated for 
FSTL1 expression by Western blotting. β-actin was used as loading control. One of 2 representative experiments in which similar results 
were obtained is shown. (d) FSTL1 immunostaining (x40 magnification) of colon adenoma sample taken from 1 patient who underwent 
endoscopic polipectomy and of surgical samples taken from tumoral (T) and non-tumoral (NT) areas of 1 patient with CRC. Staining with 
isotype control IgG is also shown. Higher magnification photomicrographs (×200) are shown in the insets. Panel shows the number of 
FSTL1-positive cells for high power field (hpf) of sections taken from 8 colon adenomas and non-tumoral (NT) and tumoral (T) areas of 
8 patients with CRC. Data are expressed as mean ± SEM.
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Fstl1 knockdown induces crc cell death 
through a caspase-dependent mechanism
Since persistent block of cell cycle progression 
leads to cell death [20], we then evaluated whether FSTL1 
inhibition affected the rate of cell survival. No significant 
change in the percentage of viable cells was seen after 48 
hours of FSTL1 AS transfection (Figure 4A, left panel 
and Supplementary Figure 2A, left panel), thus indicating 
that FSTL1 AS-mediated CRC cell growth arrest was not 
secondary to cell death. Analysis of the fraction of Annexin 
V (AV)/propidium iodide (PI)-positive cells at later time 
points showed that accumulation of FSTL1-deficient CRC 
cells in G1 phase was accompanied by increased cell death 
at 72 hours (Figure 4A, right panel and Supplementary 
Figure 2A, right panel). To delineate the mechanism 
by which FSTL1 knockdown leads to cell death, we 
evaluated the expression of active caspases by Western 
blotting. Treatment of CRC cells with FSTL1 AS increased 
expression of active forms of caspase-9, caspase 3 and its 
direct substrate, poly ADP-ribose polymerase (PARP) 
(Figure 4B and Supplementary Figure 2B). Pre-incubation 
of DLD-1 and HCT-116 cells with a pan-caspase inhibitor, 
quinolyl-valyl- aspartate-OPh (Q-VD-OPh), prevented 
FSTL1 AS-driven caspase activation (Figure 4C and 
Supplementary Figure 2C) thus abolishing the FSTL1 AS-
induced cell death (Figure 4D and Supplementary Figure 
2D). These data indicate that FSTL1 knockdown induces 
CRC cell death through a caspase-dependent mechanism.
Fstl1 knockdown augments the anti-cancer 
effects of oxaliplatin and irinotecan in crc cells
Chemotherapy-induced apoptosis is preferentially 
mediated by caspase activation [21]. To examine whether 
FSTL1 confers chemoresistance advantage to CRC 
cells, AV/PI flow cytometry analysis was performed on 
cisplatin- or -irinotecan-treated CRC cells cultured in the 
presence or absence of FSTL1 AS. Treatment of DLD-
1 cells with FSTL1 AS increased the sensibility of CRC 
cells to oxaliplatin (Figure 5A) and irinotecan (Figure 5B).
dIscussIon
Accumulating evidence supports the notion that 
factors produced by immune cells and stromal cells sustain 
growth and survival of CRC cells [22, 23]. It is also known 
that CRC cells secrete additional factors that acting in a 
paracrine/autocrine manner amplify further proliferative 
and survival signals [24]. In this study, we show that 
FSTL1 is constitutively expressed in the normal colon 
and its expression is enhanced in CRC samples relative 
to surrounding non-tumor tissues. Immunoistochemical 
analysis of colonic sections showed that both cancer cells 
and lamina propria mononuclear cells express FSTL1. Up-
regulation of the cytokine is also evident in sections of 
colon adenoma, raising the possibility that dysregulation 
of FSTL1 production occurs at early stages of colon 
carcinogenesis. Consistent with the above data, FSTL1 is 
detectable in various CRC cell lines. We show also that 
CRC cells express DIP2A, the known FSTL1 receptor, 
suggesting that FSTL1 might control CRC cell behavior. 
Indeed, knockdown of FSTL1 with a specific AS in CRC 
cell lines associates with arrest of cells in G1-phase of the 
cell cycle thus reducing cell growth. Time-course analysis 
shows also that block of cell cycle in FSTL1-deficient 
cells is followed by activation of caspases and induction 
of cell death. Moreover, FSTL1 knockdown enhances the 
susceptibility of CRC cells to chemotherapeutic drugs.
To delineate the basic mechanism by which FSTL1 
controls CRC cell growth, we assessed the effect of 
recombinant FSTL1 on HCEC-1CT, as these cells express 
DIP2A. Treatment of HCEC-1CT with recombinant 
FSTL1 activates both AKT and ERK1/2 kinases and 
eventually promotes cell growth. However, studies with 
Figure 2: Fstl1 sustains crc cells proliferation. (A) FSTL1 antisense (AS) oligonucleotide downregulates FSTL1 protein 
expression in DLD-1 and HCT-116 cells. DLD-1 (left panel) and HCT-116 (right panel) cells were transfected with either FSTL1 sense (S) 
oligonucleotide (50 nM) or increasing doses (10–50 nM) of FSTL1 AS for 48 hours. FSTL1 and β-actin were analyzed by Western blotting. 
One of 3 representative experiments is shown. (b–c) FSTL1 AS inhibits the growth of CRC cell lines. DLD-1 and HCT-116 cells were 
either left untreated (Untr) or transfected with FSTL1 AS or FSTL1 S. (B) Cell proliferation was assessed by 5-bromodeoxyuridine (BrdU) 
assay kit. Data indicate mean ± S.E.M. of 3experiments (DLD-1: FSTL1 S-transfected cells versus FSTL1 AS-transfected cells, *P < 0.001; 
HCT-116: FSTL1 S-transfected cells versus FSTL1 AS-transfected cells, †P < 0.001). (C) Cell cultures were performed as above, and the 
percentage of proliferating cells was evaluated by flow cytometry. Data indicate mean ± S.E.M. of three experiments (DLD-1: FSTL1 
S-transfected cells versus FSTL1 AS-transfected cells, *P < 0.001; HCT-116: FSTL1 S-transfected cells versus FSTL1 AS-transfected 
cells, †P < 0.001). Right panel. Representative plots are shown. (d) FSTL1 AS induces DLD-1 cells to arrest in G1 phase of cell cycle. 
DLD-1 cells were either left untreated (Untr) or transfected with FSTL1 S or AS. After 48 hours, cells were washed with PBS and cultured 
for further 24 hours. Cell cycle distribution was assessed by flow cytometry. Values are the percentages of cells in the different phases of 
cell cycle and indicate mean ± S.E.M. of 5 experiments. A significant increase in the number of cells that accumulate in G0/G1 phase (*P 
< 0.001) and a significant decrease in the number of cells in S phase (**P < 0.001) was seen in FSTL1 AS-transfected cells as compared 
with FSTL1 S-transfected cells. Right panel. Representative dot-plots showing the percentages of BrdU and/or PI-positive cells after 72 
h. (e) FSTL1 knockdown in CRC cells reduces the levels of proteins involved in late G1 cell cycle phase. DLD-1 cells were either left 
untreated (Untr) or transfected with FSTL1 AS or FSTL1 S oligonucleotide. After 48 hours cells were washed with PBS and cultured for 
further 24 hours. Cyclin D1, cyclin D2, cyclin D3, Cdk4, Cdk6, Rb, p-Rb, E2F-1, cyclin E, Cdk2 and p-Cdk2 expression was assessed by 
Western blotting. β-actin was used as loading control. One of 3 representative experiments in which similar results were obtained is shown.
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Figure 3: Fstl1 stimulates epithelial cell proliferation through an erK-dependent mechanism. (A) DIP2A is expressed 
in normal and neoplastic colon cell lines. Left panel. DIP2A RNA expression was evaluated in human colonic epithelial cell line (HCEC-
1CT) and 3 CRC cell lines (i.e. DLD-1, HCT-116 and HT-29) by real-time PCR (left panel). Levels were normalized to β-actin. Data are 
expressed as mean ± SEM. Right panel. Total proteins extracted from the same cells were evaluated for DIP2A expression by Western 
blotting (right panel). β-actin was used as loading control. One of 2 representative experiments in which similar results were obtained 
is shown. (b) FSTL1 enhances cell proliferation. HCEC-1CT cells were stimulated with recombinant human FSTL1 protein for 24, 48 
and 72 hours. Cell proliferation was assessed by using 5-bromodeoxyuridine (BrdU) assay kit. Data indicate mean ± S.E.M. of three 
experiments (*P < 0.05). (c) FSTL1 activates AKT and ERK1/2 pathways. HCEC-1CT cells were left either unstimulated or stimulated 
with recombinant FSTL1 at different time points. P-NF-kB/p65, p-AKT, p-ERK1/2 and ERK1/2 expression was assessed by Western 
blotting. β-actin was used as loading control. One of 3 representative experiments in which similar results were obtained is shown. (d–e) 
PD98059 significantly reduces FSTL1-driven cell growth. Cells were pre-treated with either wortmannin, an inhibitor of AKT (D), or 
PD98059, an inhibitor of ERK1/2 (E), prior to being stimulated with recombinant FSTL1 and cell proliferation was assessed by BrdU assay 
kit. Data indicate mean ± S.E.M. of 3 experiments (*P < 0.05; **P < 0.0001).
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pharmacologic inhibitors of such kinases show that 
FSTL1-driven cell growth is mediated by ERK1/2 and 
not AKT. These data fit with recent studies showing a 
link between the inflammatory function of FSTL1 and 
activation of ERK1/2 [25].
Our findings confirm and expand on results of 
previous studies showing an abnormal expression of 
FSTL1 in CRC tissue. For example, by comparing 
the protein component of the whole-cell extracts and 
conditioned medium of primary cancer-associated 
fibroblasts (CAF) and normal fibroblasts isolated 
from mice with azoxymethane and dextrane sodium 
sulfate induced CRC, Torres and colleagues identified 
several proteins, including FSTL1, which were 
deregulated in tumoral samples [16]. Consistently, Chen 
et al. confirmed the increased expression of FSTL1 in 
CRC cell lines and primary fibroblasts, which were 
isolated from fresh surgical specimens of CRC samples 
[17]. By using co-culture experiments, the same authors 
showed that factors secreted by normal colonic fibroblasts 
and CAF inhibited CRC cell growth, an effect that 
could be abrogated by silencing of FSTL1 or transgelin 
(TAGLN) in fibroblasts. These findings would seem to 
suggest that stromal cell-derived FSTL1 and TAGLN 
might play important roles in the suppression of CRC 
cell growth. However, the survival analyses indicated that 
FSTL1 is not a significant prognosis factor for CRC and 
FSTL1 protein expression had no significant association 
with any clinic-pathological features in colon cancer 
patients, such as tumor size, grade, sex and phase [17]. 
Differences in the experimental procedures and systems 
used to evaluate functionally the role of FSTL1 in CRC 
cell growth could explain the discrepancies between data 
published by Chen et al. and our findings. The fact that 
knockdown of FSTL1 in various CRC cell lines abrogates 
neoplastic cell growth and stimulation of colonic cell 
lines with recombinant FSTL1 enhances cell proliferation 
suggests a direct and mitogenic effect of the cytokine 
on colonic epithelial cells. Consistent with our findings 
is the demonstration that co-expression of FSTL1 with 
p53 associates with poor prognosis, in patients with 
glioblastoma [10], thus reinforcing the concept that FSTL1 
can sustain signals that amplify tumorigenesis. While this 
study was ongoing, Gu and colleagues showed that FSTL1 
expression is significantly up-regulated in CRC tissues 
compared with the paired normal tissues and the higher 
FSTL1 expression in CRC associated with the infiltrating 
depth, lymph node metastasis and poor prognosis of the 
neoplasia [18]. Moreover, enhanced expression of FSTL1 
distinctly increased cell migration and invasion in vitro 
and promoted liver metastasis of CRC in vivo.
In summary, the present study shows that FSTL1 
is up-regulated in CRC tissue and activates in CRC cells 
signals that ultimately culminate in proliferation and 
survival. Therefore, our data provide evidence for FSTL1 
being regarded as a promising target for therapeutic 
interventions in CRC patients. 
MAterIAls And Methods
Patients and samples 
Paired tissue samples were taken from the tumoral 
area and the macroscopically unaffected, adjacent, colonic 
mucosa of 20 patients who underwent colon resection 
for sporadic CRC at the Tor Vergata University Hospital 
(Rome, Italy) and used for FSTL1 evaluation by Western 
blotting and real-time PCR. Colon adenomas samples 
were taken from 6 patients who underwent to endoscopic 
polypectomy at the IRCCS Ospedale Maggiore 
Policlinico (Milan, Italy) and used for assessing FSTL1 
by immunohistochemistry. Additional samples from the 
tumoral area and the macroscopically unaffected, adjacent, 
colonic mucosa of 8 CRC patients were used for assessing 
FSTL1 by immunohistochemistry. All patients received 
neither radiotherapy nor chemotherapy prior to undergoing 
surgery. The human studies were approved by the local 
Ethics committee and each patient gave written informed 
consent.
Immunohistochemistry 
All the reagents were from Sigma-Aldrich (Milan, 
Italy) unless specified. Immunohistochemistry was 
performed on formalin-fixed, paraffin-embedded sections 
of 6 colon adenomas and paired tumoral and non-tumoral 
samples of 8 CRC patients. The sections were deparaffinised 
and dehydrated through xylene and ethanol and the antigen 
Figure 4: Fstl1 knockdown induces crc cell death through a caspase-dependent mechanism. (A) Inhibition of FSTL1 
with AS induces DLD-1 cell death. DLD-1 were either left untreated (Untr) or transfected with FSTL1 S or AS (10 nM). After 48 h cells 
were washed with PBS and cultured for further 48 (left panel) or 72 (right panel) hours. Data indicate mean ± S.E.M. of three experiments 
(FSTL1 S-transfected cells versus FSTL1 AS-transfected cells, *P < 0.001). (b) FSTL1 AS induces activation of caspases and poly ADP-
ribose polymerase. Representative Western blots for cleaved caspase-9, full-length and cleaved caspase-3, full-length and cleaved PARP 
and β-actin in extracts of DLD-1 cells transfected with either FSTL1 S or AS. One of 3 representative experiments in which similar results 
were obtained is shown. (c) Pre-incubation of DLD-1 cells with pan-caspase inhibitor Q-VD-OPh (Q-VD) inhibits caspases and PARP 
activation. Representative Western blots for cleaved caspase-9, full-length and cleaved caspase-3, full-length and cleaved PARP in extracts 
of DLD-1 cells pre-incubated with Q-VD then transfected with either FSTL1 S or AS. One of 3 representative experiments in which similar 
results were obtained is shown. β-actin was used as loading control. (d) Pre-incubation of DLD-1 cells with Q-VD abolishes FSTL1 AS-
induced cell death. Data indicate the percentage of cell death as assessed by flow cytometry analysis of Annexin V (AV) and/or propidium 
iodide (PI)-positive cells and are expressed as mean ± S.E.M of 4 experiments (FSTL1 S-transfected cells versus FSTL1 AS-transfected 
cells, *P < 0.001; FSTL1 AS-transfected cells versus FSTL1 AS + Q-VD transfected cells, **P < 0.001). 
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retrieval was performed in Tris EDTA citrate buffer (pH 7.8) 
for 30 min in a thermostatic bath at 98° C (Dako Agilent 
Technologies, Glostrup, Denmark). Immunohistochemical 
staining was performed using a rabbit policlonal antibody 
directed against human FSTL1 (final dilution 1:500, 
Thermo Fisher Scientific, Waltham, MA) at room 
temperature for 1h followed by a biotin-free HRP-polymer 
detection technology with 3,3′diaminobenzidine (DAB) as a 
chromogen (MACH 4 Universal HRP-Polymer Kit, Biocare 
Medical, Pacheco, CA). The sections were counter-stained 
with haematoxylin, dehydrated and mounted. Isotype 
control IgG-stained sections were prepared under identical 
immunohistochemical conditions as described above, 
replacing the primary antibody with a purified mouse 
normal IgG control antibody (R&D Systems, Minneapolis, 
MN). 
Inhibition of Fstl1 by Fstl1 As 
oligonucleotide
Custom LNA oligonucleotide targeting FSTL1 
was provided by Exiqon (Vedbaek, Denmark). FSTL1 
S or FSTL1 AS oligonucleotide was used at the final 
concentration of 10 nM or 50 nM for DLD-1 and HCT-
116 cells respectively. 
cell culture
The human CRC cell lines HCT-116, DLD-1 and 
HT-29, were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and the human 
colonic epithelial cell line, HCEC-1CT, was obtained 
from EVERCYTE GmbH (Vienna, Austria). Cells were 
maintained in McCoy’s 5A (HCT-116, HT-29) and RPMI 
1640 (DLD-1) medium, supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin 
(P/S) (both from Lonza, Verviers, Belgium) in a 37° C, 
5% CO2, fully humidified incubator. HCEC-1CT were 
maintained in ColoUp medium (EVERCYTE GmbH) in 
a 37° C, 5% CO2, fully humidified incubator. Cell lines 
were recently authenticated by STR DNA fingerprinting 
using the PowerPlex 18D System kit according to the 
manufacturer’s instructions (Promega, Milan, Italy). 
The STR profiles of all the cell lines matched the known 
DNA fingerprints. To investigate the role of FSTL1 in 
CRC cell growth and death, HCT-116 and DLD-1 cells 
were either left untreated or transfected with FSTL1 
sense oligonucleotide or FSTL1 AS oligonucleotide for 
48h using Opti-MEM medium and Lipofectamine 3000 
reagent (both from Life Technologies, Milan, Italy) 
according to the manufacturer’s instructions. Cells were 
then washed with Phosphate-buffered saline (PBS) and 
re-cultured with the respective fresh medium containing 
0.05% Bovine Serum Albumin (BSA) for further 24–72 
hours. In addition, DLD-1 cells were transfected with the 
specific FSTL1 AS or scrambled AS oligonucleotide (both 
used at the final concentration of 10 nM, Exiqon) for 48 
hours and then stimulated with OXL and CPT-11 (all used 
at final concentration of 20 µM) or DMSO (vehicle) for 
further 72 hours. At the end, cell viability was evaluated 
by flow cytometry.
total protein extraction and Western blotting
Paired tissue samples of tumoral and non-tumoral 
areas and colon cell lines were lysed on ice in buffer 
containing 10 mM HEPES [pH 7.9], 10 mM KCl, 0.1 
mM EthyleneDiamineTetraacetic Acid, 0.2 mM Ethylene 
Glycol-bis (β-aminoethyl ether)-N,N,N’,N’-Tetraacetic, 
and 0.5% Nonidet P40 supplemented with 1 mM 
dithiothreitol, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 
1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 
and 1 mM NaF. Lysates were clarified by centrifugation 
at 4° C, 12.000 RCF for 30 minutes, and separated on 
sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis. Blots were incubated with the following 
antibodies: FSTL1 (1:1000 final diluition, Thermo Fisher 
Scientific), cyclin D1, cyclin D2, cyclin D3, Cdk2, p-Cdk2 
(Thr14/Tyr15), Cdk4, Cdk6, Rb, E2F-1, cyclin E, caspase 
9 (p35), full-length caspase 3, p-AKT, ERK1/2, p-ERK1/2 
(1:500 final dilution, all from Santa Cruz Biotechnology 
INC, Santa Cruz, CA), p-Rb, cleaved caspase 3, PARP, 
p-NFkB (1:1000 final dilution, all from Cell Signaling 
Technology, Danvers, MA), DIP2A (1:500 final dilution, 
Novus Biologicals, Littleton, CO, USA), followed by 
horseradish peroxidase–conjugated secondary IgG 
monoclonal antibodies (all used at 1:20000 final dilution, 
Dako Agilent Technologies). After analysis, each blot 
was stripped and incubated with a mouse anti-human 
β-actin antibody (final dilution 1:5000) to ascertain 
equivalent loading of the lanes. Computer-assisted 
scanning densitometry (Chemidoc Touch Images, Biorad, 
Hercules, CA) was used to analyze the intensity of the 
immunoreactive bands. 
rnA extraction, cdnA preparation and real-
time Pcr
A constant amount of RNA (0,5 μg/sample) was 
retro-transcribed into complementary DNA (cDNA) 
Figure 5: Fstl1 knockdown enhances the toxicity of chemotherapeutic drugs. DLD-1 cells were transfected with either 
FSTL1 sense or AS (both used at 10 nM) for 48 hours and then stimulated with Irinotecan hydrochloride (A) and Oxaliplatin (b) (both used 
at a final concentration of 20 µM) or DMSO (vehicle) for further 72 hours. Data indicate the percentage of cell death as assessed by flow 
cytometry analysis of Annexin V (AV) and/or propidium iodide (PI)-positive cells and are expressed as mean ± S.E.M of 4 experiments 
(FSTL1 S-transfected cells versus FSTL1 AS-transfected cells, *P < 0.05; FSTL1 AS-transfected cells versus FSTL1 AS + irinotecan 
hydrochloride or oxaliplatin transfected cells, **P < 0.001). Representative dot-plots showing the percentages of AV- and/or PI-positive 
cells after 72 hours are also shown.
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and then 1 μl of cDNA/sample was amplified using the 
following conditions: denaturation 1 minute at 95° C; 
annealing 30 seconds, at 61° C for FSTL1, 61° C for 
DIP2A and 60° C for β-Actin, followed by 30 seconds of 
extension at 72° C. Primer sequences: FSTL1: forward, 
5′-TCTGTGCCAATGTGTTTTGTGG-3′ and reverse, 
5′-TGAGGTAGGTCTTGCCATTACTG-3′; DIP2A: 
forward, 5′-GGTGAACCTGTCATGTGTGC-3′ and 
reverse, 5′-CAGGTCCTTGAAGAGCTTGG-3′; β-actin: 
forward, 5′-AAGATGACCCAGATCATGTTTGAGACC-3′ 
and reverse, 5′-AGCCAGTCCAGACGCAGGAT-3′. 
Real-time-PCR was performed using the IQ SYBR Green 
Supermix (Bio-Rad) and RNA expression was calculated 
relative to the housekeeping β-actin gene on the base of the 
ΔΔCt algorithm.
Analysis and quantification of dld-1 and hct-
116 cells proliferation, cycle and death 
Cell proliferation was assessed using CellTrace 
Violet Cell Proliferation Kit (Thermo Fisher Scientific), 
which covalently binds cell components to yield a 
fluorescence that is divided equally between daughter cells 
at each division. Briefly, cells were either left untreated or 
transfected with FSTL1 sense or FSTL1 antisense (AS) 
oligonucleotide (both used at 10 nM or 50 nM for DLD-1 
and HCT-116 respectively). After 48 h, cells were washed 
with PBS and incubated with CellTrace according to the 
manufacturer’s instructions. After 30 min, the medium was 
removed and fresh medium containing 0.05% BSA was 
added for further 24 h. At the end, cells were collected, 
washed twice with PBS, and then incubated with 5 mg/
ml of PI for 15 min at 4 1C in the dark. CellTrace and/
or PI-positive cells were determined by flow cytometry 
and the data were analyzed using Flow-Jo software 
(FlowJo LLC, Ashland, OR). Cell proliferation was also 
assessed using a commercially available BrdU assay kit 
(Roche Diagnostics, Mannheim, Germany). DLD-1 and 
HCT-116 cells were cultured in 96-well microplates and 
either left untreated or transfected with either FSTL1 sense 
oligonucleotide or FSTL1 AS oligonucleotide (both used 
at the concentrations specified above) for 48h. BrdU was 
added to the cell cultures 6 hours before the end of the 
treatment. BrdU-positive cells were evaluated by ELISA.
For analysis of cell cycle distribution, cells were 
either left untreated or transfected with either FSTL1 sense 
oligonucleotide or FSTL1 AS oligonucleotide (both used 
at 10 nM). After 48 h, cells were washed with PBS and 
recultured with fresh medium containing 0.05% BSA for 
further 24 h. At the end, cells were pulsed with 10 mol/L 
bromodeoxyuridine for 60 minutes, fixed in 70% cold 
ethanol, and stored at 20° C for at least 3 hours. Cells then 
were denatured in 2 mol/L HCl, and stained with anti–
bromodeoxyuridine monoclonal antibody (Immunotech, 
Marseille, France) followed by fluorescein isothiocyanate–
conjugated secondary anti-mouse immunoglobulin G 
(Molecular Probes, Milan, Italy). After staining with 100 
g/mL PI, cells were analyzed by flow cytometry.
To score cell death, cells were either left untreated 
or transfected with either FSTL1 sense oligonucleotide or 
FSTL1 AS oligonucleotide (both used at 10 nM). After 
48 h, cells were washed with PBS and re-cultured with 
fresh medium containing 0.05% BSA for further 48 or 72 
h. In parallel, cells were pre-incubated in the presence or 
absence of Q-VD-OPh (R&D Systems, used at 10 µM) 
for 1 hour and then transfected with FSTL1 S or AS. Cells 
were then collected, washed twice in PBS, stained with 
FITC–annexin V (AV, 1:100 final dilution, Immunotools, 
Friesoyte, Germany) according to the manufacturer’s 
instructions and incubated with 5 mg/ml PI for 30 min at 
4 ° C, and their fluorescence was measured using FL-1 
and FL-2 channels of FACSVerse (BD Biosciences) flow 
cytometer. Viable cells were considered as AV-/PI- cells, 
apoptotic cells as AV+/PI- cells, whereas secondary 
necrotic cells were characterized by AV+/PI+ staining.
Analysis and quantification of hcec-1ct cells 
proliferation 
Cell proliferation was assessed by using a 
commercially available BrdU kit (Roche Diagnostics). 
Briefly, HCEC-1CT cells were cultured in 96-well 
microplates and stimulated with Wortmannin (final 
concentration 0,5 μM, Cell Signaling Technology) or 
PD98059 (final concentration 50 μM, Calbiochem, 
Burlington, Massachusetts) for 1 h, then treated with 
Human FSTL1 recombinant protein (final concentration 
0,75 µg/ml, Sino Biological Inc., Beijing, China) and 
cultured for 24, 48 or 72 h. BrdU was added to the cell 
cultures 6 hours before the end of the treatment and the 
assay was evaluated by ELISA.
statistical analysis
Values are expressed as mean ± SEM and results 
analyzed using the two-tailed Student t test. GraphPad 
Prims6 (GraphPad Software, La Jolla, CA), was used for 
statistical and graphical data evaluations. Significance was 
defined as P-values < 0.05.
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